407 related articles for article (PubMed ID: 28463630)
1. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
Burris HA; Infante JR; Ansell SM; Nemunaitis JJ; Weiss GR; Villalobos VM; Sikic BI; Taylor MH; Northfelt DW; Carson WE; Hawthorne TR; Davis TA; Yellin MJ; Keler T; Bullock T
J Clin Oncol; 2017 Jun; 35(18):2028-2036. PubMed ID: 28463630
[TBL] [Abstract][Full Text] [Related]
2. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.
Ansell SM; Flinn I; Taylor MH; Sikic BI; Brody J; Nemunaitis J; Feldman A; Hawthorne TR; Rawls T; Keler T; Yellin MJ
Blood Adv; 2020 May; 4(9):1917-1926. PubMed ID: 32380537
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Brahmer JR; Drake CG; Wollner I; Powderly JD; Picus J; Sharfman WH; Stankevich E; Pons A; Salay TM; McMiller TL; Gilson MM; Wang C; Selby M; Taube JM; Anders R; Chen L; Korman AJ; Pardoll DM; Lowy I; Topalian SL
J Clin Oncol; 2010 Jul; 28(19):3167-75. PubMed ID: 20516446
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Sanborn RE; Pishvaian MJ; Callahan MK; Weise A; Sikic BI; Rahma O; Cho DC; Rizvi NA; Sznol M; Lutzky J; Bauman JE; Bitting RL; Starodub A; Jimeno A; Reardon DA; Kaley T; Iwamoto F; Baehring JM; Subramaniam DS; Aragon-Ching JB; Hawthorne TR; Rawls T; Yellin M; Keler T
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35940825
[TBL] [Abstract][Full Text] [Related]
5. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
Bukowski R; Ernstoff MS; Gore ME; Nemunaitis JJ; Amato R; Gupta SK; Tendler CL
J Clin Oncol; 2002 Sep; 20(18):3841-9. PubMed ID: 12228203
[TBL] [Abstract][Full Text] [Related]
8. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Wasiuk A; Testa J; Weidlick J; Sisson C; Vitale L; Widger J; Crocker A; Thomas LJ; Goldstein J; Marsh HC; Keler T; He LZ
J Immunol; 2017 Dec; 199(12):4110-4123. PubMed ID: 29109120
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
10. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice.
Wasiuk A; Weidlick J; Sisson C; Widger J; Crocker A; Vitale L; Marsh HC; Keler T; He LZ
Cancer Immunol Immunother; 2022 Jan; 71(1):97-109. PubMed ID: 34028568
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
[TBL] [Abstract][Full Text] [Related]
12. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
[TBL] [Abstract][Full Text] [Related]
13. A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Lassen UN; Meulendijks D; Siu LL; Karanikas V; Mau-Sorensen M; Schellens JH; Jonker DJ; Hansen AR; Simcox ME; Schostack KJ; Bottino D; Zhong H; Roessler M; Vega-Harring SM; Jarutat T; Geho D; Wang K; DeMario M; Goss GD
Clin Cancer Res; 2015 Jan; 21(2):258-66. PubMed ID: 25388164
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
15. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
16. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
[TBL] [Abstract][Full Text] [Related]
17. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Topalian SL; Hodi FS; Brahmer JR; Gettinger SN; Smith DC; McDermott DF; Powderly JD; Carvajal RD; Sosman JA; Atkins MB; Leming PD; Spigel DR; Antonia SJ; Horn L; Drake CG; Pardoll DM; Chen L; Sharfman WH; Anders RA; Taube JM; McMiller TL; Xu H; Korman AJ; Jure-Kunkel M; Agrawal S; McDonald D; Kollia GD; Gupta A; Wigginton JM; Sznol M
N Engl J Med; 2012 Jun; 366(26):2443-54. PubMed ID: 22658127
[TBL] [Abstract][Full Text] [Related]
18. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Naing A; Papadopoulos KP; Autio KA; Ott PA; Patel MR; Wong DJ; Falchook GS; Pant S; Whiteside M; Rasco DR; Mumm JB; Chan IH; Bendell JC; Bauer TM; Colen RR; Hong DS; Van Vlasselaer P; Tannir NM; Oft M; Infante JR
J Clin Oncol; 2016 Oct; 34(29):3562-3569. PubMed ID: 27528724
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
Saif MW; Knost JA; Chiorean EG; Kambhampati SR; Yu D; Pytowski B; Qin A; Kauh JS; O'Neil BH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):815-24. PubMed ID: 27566701
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
LoRusso PM; Gounder M; Jalal SI; André V; Kambhampati SRP; Loizos N; Hall J; Holzer TR; Nasir A; Cosaert J; Kauh J; Chiorean EG
Invest New Drugs; 2017 Aug; 35(4):442-450. PubMed ID: 28161886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
